Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of GLP-1 on Renal Hemodynamics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Normal health demonstrated by medical examination.~* Normal values for fasting plasma glucose, total cholesterol, triglyceride, HDL, LDL, creatinine, AST, ALT and electrolyte concentrations.~Exclusion Criteria:~* Immunosuppressive treatment for the previous 12 months.~* Alcohol abuse.~* Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists that, in the opinion of the investigator, may interfere with glucose metabolism.~* Use of lithium.~* Medical treatment that affects insulin secretion or cardiovascular efficacy goals.~* Liver disease (ALT\> 2 x normal value).~* Renal impairment (creatinine\> 130 µM and / or albuminuria).~* Severe claustrophobia.~* MRI incompatible foreign bodies.

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- human glucagon-like peptide-1 (Type: ACTIVE_COMPARATOR): Intervention:~Drug: human glucagon-like peptide-1 Other names: GLP-1
- Placebo (Type: PLACEBO_COMPARATOR): Intervention:~Drug: Placebo (saline) Other names: Placebo for human glucagon-like peptide-1

Based on this trial design, predict the completion outcome and termination type (if applicable).